Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RN624 · 3 trials · 4 indications
Participants assessed their average daily pain during the past 24 hours on an 11--point NRS ranging from 0 (no pain) to 10 (worst possible pain) with lower scores indicating less pain. Week 6 score was calculated as the mean of average daily pain NRS scores over the past 7 days. The change from baseline was calculated using difference between Week 6 mean score and Baseline mean score.
AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 12 weeks after last dose that were absent before treatment in this study or that worsened relative to pretreatment state. AEs included both SAEs and non-serious adverse events.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | PLACEBO_COMPARATOR | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RN624 | DRUG | 50 mcg/kg |
| Placebo | DRUG | placebo |
| RN624 (PF-04383119) | DRUG | 50 mcg/kg |
Inclusion Criteria: * Male or female of any race, at least 18 years of age. * Patients must have pain present for more than 3 months after healing of the herpes zoster skin rash. * Has a pain score at screening that qualifies. * Completes at least 3 average daily pain diaries during the 3 days prio...
RN624 is an investigational small molecule being studied for pain, specifically for postherpetic neuralgia and osteoarthritis. It has been evaluated in Phase 2 clinical trials for moderate to severe osteoarthritis knee pain and for pain of post-herpetic neuralgia.
RN624 is being developed by Pfizer, Inc. (NYSE: PFE). The company has sponsored Phase 2 clinical trials of the drug for pain indications including osteoarthritis and postherpetic neuralgia.
RN624 is in Phase 2 clinical development. It has completed two Phase 2 trials, one for osteoarthritis knee pain and one for postherpetic neuralgia pain. It is not approved and remains investigational.
RN624 has been studied in three completed Phase 2 trials: NCT00394563 for moderate to severe osteoarthritis knee pain, NCT00399490 as an open-label extension study for osteoarthritis, and NCT00568321 for pain of post-herpetic neuralgia. All trials are completed.
RN624 is a small molecule, but its specific molecular target has not been disclosed in the available information. It is being studied for pain relief in conditions like osteoarthritis and postherpetic neuralgia.
RN624 is not the same as tanezumab. RN624 is a small molecule, while tanezumab is a monoclonal antibody. They are distinct drug candidates developed by Pfizer for pain indications.